SLU-PP-332 5 mg*10vials Kit
$165.00
Description
🧪 Product Profile: SLU-PP-332
Product Name: SLU-PP-332
CAS Number: 303760-60-3
Synonyms: 4-Hydroxy-N’-(2-naphthylmethylene)benzohydrazide; (E)-4-Hydroxy-N’-(naphthalen-2-ylmethylene)benzohydrazide
Molecular Formula: C₁₈H₁₄N₂O₂
Molecular Weight: 290.32 g/mol
Chemical Structure: Hydrazone derivative with a naphthalene ring and para-hydroxybenzoyl group (SMILES: C(NN=CC1=CC=C2C(=C1)C=CC=C2)(=O)C1=CC=C(O)C=C1)
Purity: ≥99% (HPLC verified)
Formulation: White to off-white solid powder; soluble in DMSO (2 mg/mL when warmed), with predicted density of 1.20±0.1 g/cm³ and pKa of 8.44±0.15
🔬 Mechanism of Action
SLU-PP-332 is a pan-estrogen-related receptor (ERR) agonist with high affinity for ERRα (EC₅₀=98 nM), ERRβ (230 nM), and ERRγ (430 nM). It activates metabolic pathways analogous to aerobic exercise by:
- Enhancing Mitochondrial Function: Upregulates mitochondrial respiration and biogenesis in skeletal muscle, increasing fatty acid oxidation and cellular energy expenditure.
- Modulating Gene Expression: Induces peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and pyruvate dehydrogenase kinase 4 (PDK4), shifting metabolism toward fat utilization.
- Improving Muscle Oxidative Capacity: Promotes type IIa oxidative muscle fiber formation and enhances exercise tolerance without stimulating physical activity.
📊 Preclinical Efficacy (Murine Models)
| Parameter | Effect |
|---|---|
| Energy Metabolism | Increases resting energy expenditure by 22%; shifts substrate utilization to fatty acid oxidation (45% reduction in respiratory exchange ratio) |
| Body Composition | Reduces adiposity by 12% in obese mice after 4 weeks of treatment (without changes in food intake) |
| Exercise Performance | Extends running time by 70% and distance by 45% in normal-weight mice; enhances muscle glycogen utilization |
| Metabolic Health | Improves glucose tolerance (30% lower AUC in GTT), reduces hepatic steatosis, and normalizes lipid profiles in diet-induced obese mice |
| Molecular Biomarkers | Upregulates Per1/Per2 (circadian rhythm) and Ddit4 (energy stress response) genes; increases mitochondrial DNA content by 58% in gastrocnemius muscle |
💡 Research Applications
- Metabolic Disease Modeling: Tool for studying obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD) pathogenesis.
- Exercise Physiology: Investigational agent to dissect ERR-mediated signaling pathways in muscle adaptation and mitochondrial biogenesis.
- Aging Research: Potential modulator of age-related muscle wasting (sarcopenia) and metabolic decline.
- Drug Discovery: Lead compound for developing orally active ERR agonists with improved pharmacokinetic properties.
⚙️ Pharmaceutical Development
- Stage: Preclinical (discovered by Washington University School of Medicine and St. Louis College of Pharmacy)
- Formulation Challenges: Currently administered via injection; research ongoing to develop oral formulations using cyclodextrin complexation or lipid-based delivery systems.
- Safety Profile: No overt toxicity observed in murine studies (1-month treatment); no impact on appetite or reproductive parameters.
- Intellectual Property: Covered by pending patents for metabolic disorder treatment and exercise mimetics.
📦 Commercial Specifications
- Storage: Stable at 2-8°C for ≥24 months in desiccated form; DMSO solutions stable at -80°C for 6 months.
- Supply: Available from specialized chemical suppliers (TargetMol, Mesochem) with minimum order quantities of 5 mg; bulk production capacity up to 1 ton/year.
- Quality Control: Batch testing includes HPLC purity, mass spectrometry verification, and solubility assessment in DMSO.
⚠️ Research Limitations
- Species Translation: Efficacy尚未在非啮齿类动物中验证; human ERR isoform affinity may differ.
- Long-term Safety: Potential off-target effects on reproductive tissues due to ERR homology with estrogen receptors require further evaluation.
- Delivery Barriers: Poor aqueous solubility and first-pass metabolism hinder oral bioavailability.



